 WILMETTE, Ill., Aug. 03, 2021 GLOBE NEWSWIRE -- Monopar Therapeutics Inc. Nasdaq: MNPR, a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced clearance from the US Food and Drug Administration FDA to proceed under its IND with an open-label Phase 1b dose-escalation trial evaluating camsirubicin plus growth factor support pegfilgrastim in patients with advanced soft tissue sarcoma ASTS. The Company anticipates dosing the first patient in the trial in the fourth quarter of this year. 